Heart disease remains the leading cause of death in the United States, with the American Heart Association reporting over 940,000 deaths in 2022. The annual healthcare costs for cardiovascular conditions are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050. Into this escalating crisis steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company applying artificial intelligence, epigenetics, and genetics to detect coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
What makes Cardio Diagnostics' approach distinct is its ability to detect coronary heart disease earlier and with high sensitivity. Traditional diagnostic tools have limitations, often missing certain presentations of the disease. By leveraging epigenetic markers—chemical modifications to DNA that can indicate disease states—combined with AI-driven analysis, the company aims to improve detection rates and enable earlier intervention.
The company's recent commercial and regulatory milestones provide additional context to its investment thesis. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups, with one person dying every 34 seconds. The scale of the problem underscores the potential impact of Cardio Diagnostics' technology.
For more information on the company's latest news and updates, visit the company's newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause actual results to differ materially. Factors that could cause such differences include those described in the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
